Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Texas Roadhouse, Inc. announced its Q1 2026 financial results, highlighting a 12.8% increase in total revenue and an 8.6% increase in net income versus the prior year. Comparable restaurant sales grew by 7.1%. The company opened six new restaurants during the quarter, including franchise locations, and invested heavily in capital expenditures and a…
Catalyst Pharmaceuticals, a U.S.-based biopharmaceutical company focused on rare diseases, has canceled its first quarter 2026 earnings conference call scheduled for May 12, following the announcement of its pending acquisition by Angelini Pharma S.p.A. The company will still release its Q1 2026 financial results on May 11 as planned.
WillScot Holdings Corporation, a provider of innovative temporary space solutions, announced a quarterly cash dividend of $0.07 per share payable on June 17, 2026, to shareholders of record as of June 3, 2026. The company serves industries including construction, manufacturing, healthcare, government, energy, and education with a comprehensive prod…
Full House Resorts reported a strong first quarter for 2026 with consolidated revenues of $74.4 million and a 14.7% increase in Adjusted EBITDA to $13.2 million. The growth was primarily driven by American Place Casino's 7.1% revenue increase and operational improvements in Colorado properties. The company is advancing construction plans for a perm…
Outset Medical released its Q1 2026 financial results, showing a 6% revenue decline but a significant gross margin expansion to 43.4%. Despite lower product revenue, recurring service revenue remained stable. The company reduced net loss compared to the prior year and maintained a strong cash position. Outset reiterated 2026 revenue guidance of $12…
Scorpio Tankers Inc. announced a proposed private offering to reopen its 1.75% convertible senior notes due 2031 by issuing an additional $150 million, with an option to increase by $22.5 million. Concurrently, the company plans to use part of the proceeds to repurchase its common stock, particularly shares sold short during the offering. The notes…
Amneal Pharmaceuticals reported a solid start to 2026 with a 4% increase in Q1 net revenue to $723 million and a 411% jump in net income to $62 million compared to Q1 2025. Adjusted EBITDA rose 19% to $202 million, driven by strong performance across its Specialty and Affordable Medicines segments. The company also reaffirmed its previously raised …
Serve Robotics announced robust first quarter 2026 results with revenue of $3.0 million, up 238% sequentially and 578% year-over-year, reflecting expansion across delivery and healthcare robotics following the acquisition of Diligent Robotics. The company expanded operations to 44 cities in 14 states, grew its robot fleet to approximately 2,000 uni…
Quest Resource Holding Corporation announced its Q1 2026 financial results showing a 4.8% sequential revenue increase and 6.1% rise in gross profit from Q4 2025, despite year-over-year declines. The company onboarded new customers, including a large quick-service restaurant franchisee, and refinanced debt to reduce interest expenses. Quest focused …
Bluejay Diagnostics provided a Q1 2026 update highlighting progress in clinical enrollment, manufacturing readiness, and regulatory strategy for its Symphony IL-6 test aimed at rapid sepsis patient monitoring. The company enrolled approximately 680 patients in its pivotal SYMON-II study, advanced manufacturing with contract manufacturer Sanyoseiko,…
Celldex has successfully completed enrollment for its Phase 3 studies in chronic spontaneous urticaria (CSU) six months ahead of schedule, with topline data expected in Q4 2026 and a planned BLA submission in 2027. Ongoing studies include Phase 3 trials for cold urticaria and symptomatic dermographism, and a Phase 1 study of CDX-622 in asthma. The …
Tectonic Therapeutic announced its Q1 2026 financial results highlighting significant clinical progress with TX45 and TX2100 drug candidates targeting pulmonary hypertension and hereditary hemorrhagic telangiectasia (HHT). Key milestones include near completion of patient enrollment in TX45 APEX Phase 2 trial, initiation of TX45 ALPINE Phase 2 tria…
Prairie Operating Co., an independent energy company focused on oil and natural gas development in the Denver-Julesburg Basin, will release its first quarter 2026 financial and operating results on May 14, 2026, followed by a conference call on May 15. The company invites analysts and investors to participate as it provides updates on recent develo…
Clearway Energy, Inc. reported Q1 2026 results with a net loss of $68 million, Adjusted EBITDA of $257 million, and reassured full-year 2026 CAFD guidance of $470 to $510 million. The company progressed significant growth initiatives, including completion of the Honeycomb Phase 1 battery storage facilities, acquisition of the Cardinal solar portfol…
Xenon Pharmaceuticals announced positive topline Phase 3 data from the X-TOLE2 study for azetukalner in focal onset seizures, leading to an anticipated New Drug Application submission to the FDA in Q3 2026. The company continues enrollment in additional Phase 3 trials for epilepsy and neuropsychiatric indications and advances early-stage pain candi…
BridgeBio Pharma reported first quarter 2026 financial results highlighting $194.5 million in total revenues, primarily driven by $180.6 million from U.S. sales of its ATTR-CM drug Attruby. The company continues to see strong commercial traction for Attruby, including new approval in Brazil. It has submitted its first NDA for BBP-418 (LGMD2I/R9) an…
Voyager Therapeutics announced its first quarter 2026 financial results and operational progress, highlighting completion of IND-enabling toxicology studies for its tau silencing gene therapy VY1706, with first-in-human dosing expected in the second half of 2026 for Alzheimer's disease. The company maintains a strong cash position of $172 million, …
Senseonics Holdings, Inc. reported robust first quarter 2026 financial results with revenue growing 87% year-over-year to $11.7 million. The company highlighted significant commercial progress, including the US launch of Eversense 365 and expansion into Europe. They raised over $100 million in equity and debt financing to support ongoing product co…
Akamai Technologies reported first quarter 2026 revenue of $1.074 billion, a 6% increase year-over-year driven primarily by 40% growth in Cloud Infrastructure Services and 11% growth in security revenue. The company announced a $1.8 billion seven-year commitment from a leading U.S.-based frontier model provider in AI, validating Akamai's position i…
SIGA Technologies announced its financial results for Q1 2026, reporting net losses but highlighted planned deliveries of $13 million oral TPOXX to an international customer and $26 million IV TPOXX to the U.S. Government Strategic National Stockpile by Q3 2026. The company also secured an exclusive license agreement for oral TPOXX commercializatio…
Annexon, Inc. reported its first quarter 2026 financial results and detailed significant progress and upcoming milestones across its neuroinflammatory disease therapy portfolio. Key upcoming catalysts include topline Phase 3 data for vonaprument targeting Geographic Atrophy (GA) expected in Q4 2026, regulatory review of tanruprubart for Guillain-Ba…
Denali Therapeutics announced FDA accelerated approval and U.S. commercial launch of AVLAYAH for Hunter syndrome, the first medicine leveraging the transferrin receptor to cross the blood-brain barrier. The company reported progress across its pipeline targeting Alzheimer's, frontotemporal dementia, Sanfilippo syndrome, Pompe disease, and Parkinson…
Gevo, Inc. announced solid financial and operational results for Q1 2026, exceeding expectations despite seasonality in ethanol margins. The company progressed on its debottlenecking and expansion projects at its North Dakota facility to increase low-carbon ethanol output by over 10% next year and aims to double capacity by 2028. Gevo also launched…
Corvus Pharmaceuticals reported positive Phase 1 clinical data for its lead drug candidate, soquelitinib, in atopic dermatitis and initiated Phase 2 trials including additional indications like hidradenitis suppurativa and asthma. The company also continues enrolling in a Phase 3 trial for T cell lymphoma and collaborates with NIAID on a rare disea…
Research Frontiers Inc. announced its first-quarter 2026 financial results, noting revenue was impacted by the timing of license agreement recognition and absence of prior year upfront revenue. The company advanced multiple strategic initiatives across automotive, aircraft, and architectural sectors using its SPD-Smart light-control technology. Whi…
